secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000950170-24-123303
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology Q3 cash $57.7M; initial CRDF-004 data expected by year-end
---------------------------------------------------------------------------

- Cash, equivalents, and short-term investments of $57.7M as of Sept 30, 2024.
- Net cash used in operations: $10.5M in Q3 2024, up from $8.0M in Q3 2023.
- Total operating expenses $12.8M for Q3 2024, an increase of $1.8M YoY.
- Initial data readout from first-line RAS-mutated mCRC CRDF-004 trial expected by end of 2024.
- Phase 2 trial in second-line KRAS-mutant mCRC published in Journal of Clinical Oncology; bev naïve patients had ORR 77% and mPFS 14.9 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000095017024123303/0000950170-24-123303-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000095017024123303/crdf-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-123303

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer